Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Diluted Average) (2019 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $65.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 6.54% to $65.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.0 million through Dec 2025, up 6.54% year-over-year, with the annual reading at $65.0 million for FY2025, 6.54% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $65.0 million at Rhythm Pharmaceuticals, up from $64.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $65.0 million in Q4 2025, with the low at $48.5 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $56.5 million, with a median of $57.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 13.92% in 2021, then grew 0.3% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $49.6 million in 2021, then increased by 5.08% to $52.1 million in 2022, then rose by 10.65% to $57.7 million in 2023, then increased by 5.76% to $61.0 million in 2024, then increased by 6.54% to $65.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $65.0 million, $64.3 million, and $63.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.